Combination therapy for triple-positive breast cancer before surgery
Part of Cancer, Skin clinical trials.
This trial tests whether a combination of targeted therapies and hormone therapy can shrink triple-positive breast cancer before surgery. It is for women with stage II or III breast cancer that has not yet been treated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II or III breast cancer that is triple-positive (HR+ and HER2+).
- You are a woman between 18 and 75 years old.
- You have not had any prior treatment for this breast cancer (like chemo, radiation, or targeted therapy).
- You have a tumor that can be measured on scans and your organs are working well.
- You are either premenopausal, perimenopausal, or postmenopausal.
- You are willing to avoid pregnancy during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a combination of three anti-HER2 drugs plus a CDK4/6 inhibitor before surgery for women with a type of breast cancer that is both HER2-positive and ER-positive. It aims to see if this treatment can shrink tumors more effectively before surgery.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests a combination of two drugs (serplulimab and trastuzumab rezetecan) given before surgery to shrink tumors in people with early-stage triple-negative breast cancer. The goal is to see if this treatment helps remove more cancer cells before the main surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.